Anthem Biosciences Limited (BOM:544449)

Market Cap	423.48B
Revenue (ttm)	21.24B +14.8%
Net Income	5.92B +31.1%
EPS	10.43 +29.7%
Shares Out	n/a
PE Ratio	71.56
Forward PE	58.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,117
Open	760.10
Previous Close	760.10
Day's Range	741.00 - 761.85
52-Week Range	579.45 - 873.25
Beta	n/a
Analysts	Strong Buy
Price Target	879.43 (+16.43%)
Earnings Date	May 19, 2026

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Commercial Physical and Biological Research
• Founded: 2006
• Employees: 1,825
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544449

Financial Performance

In fiscal year 2026, Anthem Biosciences's revenue was 21.24 billion, an increase of 14.80% compared to the previous year's 18.50 billion. Earnings were 5.92 billion, an increase of 31.14%.